|
1
|
Burris HA III, Moore MJ, Andersen J, et
al: Improvements in survival and clinical benefit with gemcitabine
as first line therapy for patients with advanced pancreas cancer: a
randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
|
|
2
|
Oettle H, Pelzer U, Stieler J, Hilbig A,
et al: Oxaliplatin/folinic acid/5-fluorouracil [24h] (OFF) plus
best supportive care versus best supportive care alone in
second-line therapy of gemcitabine-refractory advanced pancreatic
cancer (CONKO 003). J Clin Oncol. 23(Suppl): 40312005.PubMed/NCBI
|
|
3
|
Nakachi K, Furuse J, Ishii H, Suzuki E and
Yoshino M: Prognostic factors in patients with
gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol.
37:114–120. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morizane C, Okusaka T, Furuse J, et al: A
phase II study of S-1 in gemcitabine-refractory metastatic
pancreatic cancer. Cancer Chemother Pharmacol. 63:313–319. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morizane C: A case of
gemcitabine-refractory pancreatic cancer responsive to second-line
chemotherapy using S-1. Jpn J Clin Oncol. 37:9732007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Todaka A, Fukutomi A, Boku N, et al: S-1
monotherapy as second-line treatment for advanced pancreatic cancer
after gemcitabine failure. Jpn J Clin Oncol. 40:567–572. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ueno H, Okusaka T, Ikeda M, Takezako Y and
Morizane C: An early phase II study of S-1 in patients with
metastatic pancreatic cancer. Oncology. 68:171–178. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Funakoshi A, Senju T and Sumii T: Two
cases of advanced pancreatic cancer with cervical lymph node or
liver metastasis responding well to S-1 monotherapy. Gan To Kagaku
Ryoho. 33:1505–1509. 2006.(In Japanese).
|
|
9
|
Ducreux M, Rougier P, Pignon JP, et al: A
randomised trial comparing 5-FU with 5-FU plus cisplatin in
advanced pancreatic carcinoma. Ann Oncol. 13:1185–1191. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rougier P, Zarba J, Ducreux M, et al:
Phase II study of cisplatin and 120-hour continuous infusion of
5-fluorouracil in patients with advanced pancreatic adenocarcinoma.
Ann Oncol. 4:333–336. 1993.PubMed/NCBI
|
|
11
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
12
|
Jemal A, Siegel R, Xu J and Ward E: Cancer
statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
|
|
13
|
Conroy T, Desseigne F, Ychou M, et al:
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N
Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dahan L, Bonnetain F, Ychou M, et al:
Combination 5-fluorouracil, folinic acid and cisplatin
(LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in
metastatic pancreatic cancer: final results of a randomised
strategic phase III trial (FFCD 0301). Gut. 59:1527–1534. 2010.
View Article : Google Scholar
|
|
15
|
Androulakis N, Syrigos K, Polyzos A, et
al: Oxaliplatin for pretreated patients with advanced or metastatic
pancreatic cancer: a multicenter phase II study. Cancer Invest.
23:9–12. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ulrich-Pur H, Raderer M, Verena Kornek G,
et al: Irinotecan plus raltitrexed vs raltitrexed alone in patients
with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br
J Cancer. 88:1180–1184. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Oettle H, Arnold D, Esser M, Huhn D and
Riess H: Paclitaxel as weekly second-line therapy in patients with
advanced pancreatic carcinoma. Anticancer Drugs. 11:635–658. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boeck S, Weigang-Köhler K, Fuchs M, et al:
Second-line chemotherapy with pemetrexed after gemcitabine failure
in patients with advanced pancreatic cancer: a multicenter phase II
trial. Ann Oncol. 18:745–751. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Pelzer U, Kubica K, Stieler I, et al: A
randomized trial in patients with gemcitabine refractory pancreatic
cancer. Final results of the CONKO 003 study. J Clin Oncol.
26(Suppl 15): 45082008.
|
|
20
|
Lubner SJ, Schelman WR, Mulkerin D, Holen
KD, Seo S and LoConte NK: Phase II study of oxaliplatin, high-dose
capecitabine, and sorafenib in patients with advanced pancreatic
cancer. J Clin Oncol. 28(Suppl 15): 41432010.
|
|
21
|
Starling N, Hawkes EA, Chau I, et al: A
dose-escalation study of gemcitabine plus oxaliplatin in
combination with imatinib in patients with gemcitabine-refractory
advanced pancreatic adenocarcinoma. Ann Oncol. Jul 12–2011.(E-pub
ahead of print).
|
|
22
|
Nakai Y, Isayama H, Sasaki T, et al:
Impact of S-1 in patients with gemcitabine-refractory pancreatic
cancer in Japan. Jpn J Clin Oncol. 40:774–780. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alsamarai S, Zergebel C, Zhang J, Furuie
T, Urrea PD and Saif MW: Long term survival on S-1 monotherapy in a
patient with recurrent stage IV pancreatic cancer. JOP. 9:185–191.
2008.PubMed/NCBI
|
|
24
|
Yoshino T, Fukutomi A and Boku N:
Chemotherapy-naïve advanced pancreatic cancer with multiple liver
metastases successfully treated by S-1 monotherapy. A case report.
Gan To Kagaku Ryoho. 33:1521–1523. 2006.(In Japanese).
|
|
25
|
Koizumi W, Narahara H, Hara T, et al: S-1
plus cisplatin versus S-1 alone for first-line treatment of
advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet
Oncol. 9:215–221. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ajani JA, Rodriguez W, Bodoky G, et al:
Multicenter phase III comparison of cisplatin/S-1 with
cisplatin/infusional fluorouracil in advanced gastric or
gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin
Oncol. 28:1547–1553. 2010. View Article : Google Scholar
|
|
27
|
Togawa A, Yoshitomi H, Ito H, et al:
Treatment with an oral fluoropyrimidine, S-1, plus cisplatin in
patients who failed postoperative gemcitabine treatment for
pancreatic cancer: a pilot study. Int J Clin Oncol. 12:268–273.
2007. View Article : Google Scholar : PubMed/NCBI
|
